Complexities, challenges, and clinical implications of small cell lung cancer

Small cell lung cancer (SCLC) is an aggressive, malignant form of lung cancer known for its rapid growth and early metastasis. SCLC accounts for 15% of all lung cancer, is often tobacco-use related, and extensive-stage (ES)-SCLC has a five-year survival rate of only about 5%. SCLC is marked by its usual late diagnosis, aggressive nature, intratumoral heterogeneity, and developed resistance to chemotherapy with near universal loss of tumor suppressors TP53 and RB1. It is classified as a neuroendocrine tumor, though a subset lacks these features. There are four subtypes of SCLC based on the expression of key transcription factors, SCLC-A (ASCL1), SCLC-N (NEUROD1), SCLC-P (POU2F3), and SCLC-I (an inflamed subtype). Studies indicate that each subtype has unique vulnerabilities that could benefit from specialized treatment plans. Therapeutic strategies targeting neuroendocrine DLL3 overexpression in the notch signaling pathway or targeting of DNA repair enzyme PARP1 have had varied success There has been little progress in the last 30 years for early detection, improved therapies, or prevention of SCLC. Immune checkpoint inhibitors in combination with chemotherapy has shown some improvement in patient overall survival though more successful therapies are needed. Currently, SCLC research often relies on single-platform data, which may not capture the complexity of the disease. The lack of comprehensive multi-omics data in small cell lung cancer (SCLC) has hindered advancements in understanding its biology and developing effective therapies.